Small Cell Lung Cancer With Paraneoplastic Cushing Syndrome Treated With Immunochemotherapy

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 negative; low tumor mutation burden; microsatellite stable

Metastatic Site: liver, abdominal wall, left ilium

He lived 20 months after diagnosis. After repeated treatment responses and later progression, he died in September 2023 from respiratory and cardiac failure during a severe infection following treatment-related myelosuppression.

PubMed CentralRead more →

Stage 4 HR-positive breast cancer: stable disease on ribociclib

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: left iliac bone

Metastatic HR-positive, HER2-negative breast cancer remained without progression as of October 2024 while she continued ribociclib 400 mg plus letrozole after SBRT to a left iliac bone metastasis.

PubMed CentralRead more →

Deltra: Stage IV Breast Cancer

Patient Info: Deltra James, Female, Under 40 | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

As of December 2024, Deltra James was living with de novo Stage IV triple-negative metastatic breast cancer and advocating for sexual-health and intimacy conversations in metastatic care.

Stage IV Colorectal Adenocarcinoma: Lindy's Patient Story

Patient Info: Lindy Avalos, Female, Under 40 | Stage IV

Metastatic Site: lymph nodes, liver, lungs

As of December 2024, Lindy was on maintenance chemotherapy after 6 months of oxaliplatin and said she had been responding fairly well, though she was still living with Stage IV disease.

The Patient StoryRead more →

Colon cancer recurring in the spleen with a serious splenic abscess

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: KRAS wild-type, NRAS wild-type, BRAF wild-type

Metastatic Site: spleen

More than 5 years after his 2016 colectomy, he was treated for metastatic recurrence. Disease was assessed as stable during systemic therapy, and he later recovered well after splenectomy for confirmed splenic metastasis.

PubMed CentralRead more →

Stage IV lung adenocarcinoma: ROS1 fusion detected after immunotherapy resistance and partial response to entrectinib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial lung adenocarcinoma markers supported lung origin; PD-L1 <1%, no target found at first. Later testing found CD74-ROS1 fusion.

Metastatic Site: brain, bilateral lung lesions

As of December 2024, repeat imaging after entrectinib showed partial response in lung disease and regression of brain metastases, with the patient stable and willing to continue treatment.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Leah's Patient Story

Patient Info: Leah Phillips, Female, 40s | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Not reported

As of December 2024, Leah was recovering well a few weeks after right-middle-lobe lobectomy, but remained a Stage IV EGFR-mutated lung cancer patient needing ongoing treatment and follow-up.

MD AndersonRead more →

Stage IV Colorectal Cancer: Kate's Patient Story

Patient Info: Kate, Female, Under 40 | Stage IV

Metastatic Site: outside the colon (exact site not specified)

As of December 2024, Kate was still receiving chemotherapy, but scans after 4 rounds showed shrinkage and no new spread.

The Patient StoryRead more →

Stage IV ROS1 Non-Small Cell Lung Cancer: Ashley's Survivor Story

Patient Info: Ashley, Female, Under 40 | Stage IV

Biomarkers: ROS1-rearranged

Metastatic Site: spine/bone

As of December 2024, Ashley described herself as having no evidence of active disease while continuing nightly ROS1-targeted therapy.

The Patient StoryRead more →

Stage IV lung adenocarcinoma: clinical complete remission with pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: No EGFR/ALK/BRAF driver alteration; PD-L1 <1%; high TMB in tissue and blood; immune-cell markers reported.

Metastatic Site: bilateral lungs, mediastinal lymph nodes, right hilar…

Clinical complete remission by RECIST while receiving pembrolizumab monotherapy for driver-negative, PD-L1-negative, high-TMB Stage IV lung adenocarcinoma.

PubMed CentralRead more →

Stage IV Lung Cancer: Natalie's Patient Story

Patient Info: Natalie, Female | Stage IV

Metastatic Site: lungs, lymph nodes

As of December 2024, Natalie had restarted chemotherapy after progression, and the current chemotherapy had stopped growth for the moment while she continued transplant evaluation.

The Patient StoryRead more →

Stage IV luminal B breast cancer with liver, bone, and bone marrow metastases

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 20% positive; HER2-negative; Ki-67 60%; luminal B

Metastatic Site: liver, bone, bone marrow

The patient had marked clinical and hematologic improvement on leuprorelin, letrozole, ribociclib, and zoledronic acid, with sustained complete remission reported for 4 months from September to December 2023 and monthly follow-up advised.

PubMed CentralRead more →

Metastatic EGFR-positive lung adenocarcinoma: osimertinib cardiomyopathy managed with SGLT2 inhibitor support

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR-positive; specific EGFR sequence variant not reported in extracted case text

As of December 2024, he remained clinically stable and asymptomatic 12 months after osimertinib rechallenge with empagliflozin, losartan, metoprolol, and close cardiac monitoring; the extracted case focuses on cardiotoxicity management rather than tumor response.

PubMed CentralRead more →

Breast Cancer Recurrence in the Small Intestine and Bone More Than 5 Years After Diagnosis

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial ER-positive, PR-positive, HER2-negative; metastatic lesion ER-negative, PR-negative, triple negative

Metastatic Site: small intestine, bone, right fallopian tube

More than 5 years after her December 2018 diagnosis, she was alive at 1-year follow-up after metastatic recurrence, with multiple bone metastases still present.

PubMed CentralRead more →

Stage IV ALK Lung Cancer: Amanda's Patient Story

Patient Info: Amanda, Female, Under 40 | Stage IV

Biomarkers: ALK-rearranged

Metastatic Site: pleural fluid, right clavicle lymph node

As of December 2024, Amanda had lived with Stage IV ALK-positive lung cancer for about 2 years and was taking 8 targeted-therapy pills daily.

The Patient StoryRead more →

Stage IV Lung Adenocarcinoma With Delayed Pembrolizumab-Related Pneumonitis

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: contralateral lung

After brachytherapy and continued pembrolizumab, imaging 1 year later showed a smaller right hilar lesion with otherwise stable disease. She later recovered from delayed pembrolizumab-related pneumonitis after immunotherapy had been stopped.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Filipe's Patient Story

Patient Info: Filipe, Male, Under 40 | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain, bone, left lung, kidney

As of November 2024, Filipe was living with ongoing Stage IV EGFR exon 19-mutated lung cancer after initial response to osimertinib, later progression and current amivantamab plus chemotherapy.

The Patient StoryRead more →

Stage IV Colorectal Cancer: Monica's Patient Story

Patient Info: Monica, Female, Under 40 | Stage IV

Metastatic Site: lymph nodes

As of November 2024, Monica was still in active treatment, but lymph nodes had shrunk after chemotherapy and further surgery plus additional chemotherapy were planned.

The Patient StoryRead more →

Stage IV Breast Cancer: Nina's Survivor Story

Patient Info: Nina, Female, Under 40 | Stage IV

Metastatic Site: Spine

As of November 2024, Nina had Stage IV metastatic breast cancer with prior spine metastasis, remained on indefinite infusions and medications, and had current scans showing no evidence of disease.

The Patient StoryRead more →

Stage IV Colorectal Adenocarcinoma: Casandra's Patient Story

Patient Info: Casandra, Female, Under 40 | Stage IV

Metastatic Site: Liver, lungs

As of November 2024, Casandra had been diagnosed just over a month earlier and was receiving aggressive every-2-week systemic therapy with the goal of shrinking disease enough to create surgical options.

The Patient StoryRead more →

Lung Adenocarcinoma With Immune-Related Abdominal Inflammation and Later Bone Progression

Patient Info: Anonymized, male | Stage IV

Biomarkers: PD-L1 30%; KRAS G13X mutation; EGFR/ALK/ROS1 negative

Metastatic Site: bone

After several periods of response or stability, lymph-node progression recurred and bone progression was documented in July 2024. Another treatment line was being planned.

PubMed CentralRead more →

Stage IV Triple-Negative Breast Cancer: Deltra's Patient Story

Patient Info: Deltra James, Female, Under 40 | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

As of November 2024, Deltra James was living with de novo Stage IV triple-negative metastatic breast cancer and discussing dating, confidence, and emotional safety after diagnosis.

Stage 4 ALK-positive lung cancer: remission on lorlatinib

Patient Info: Anonymized, Male, Under 40 | Stage IV

Biomarkers: ALK-positive rearrangement; TTF-1-positive

Metastatic Site: bilateral lungs, mediastinal lymph nodes, bone, liver,…

Metastatic ALK-positive lung adenocarcinoma remained in radiologic and clinical remission on lorlatinib after CNS progression on earlier ALK-directed therapy and stereotactic radiosurgery.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Nina's Survivor Story

Patient Info: Nina, Female, Under 40 | Stage IV

Biomarkers: HER2-positive; broad hereditary genetic testing negative

Metastatic Site: spine

As of November 2024, Nina described being in a no-evidence-of-disease phase, while continuing treatment because of her Stage IV HER2-positive metastatic breast cancer history.

The Patient StoryRead more →